Insulet Corporation Stock News

ACTON, Mass.--( BUSINESS WIRE )--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that manageme

Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

Gainers Peak Bio, Inc. (NASDAQ: PKBO) shares surged 105.8% to close at $7.82 on Friday. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Lade

Gainers Peak Bio, Inc. (NASDAQ: PKBO) jumped 115% to $8.17. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Ladenburg Thalmann initiated cov

U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session. Willdan Group, Inc. (NASDAQ: WLDN) surged 27.6% to

Investors are cheering the company's strong Q3 results.

Upgrades Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to Buy. For the third quarter, Advanced Energy Indus had an EPS of $2.12, compared to yea

Over the past 3 months, 5 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company

Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday. BioAtla, Inc. (NASDAQ: BCAB) rose 47.5% to $9.38 in pre-market trading aft

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. XPeng Inc. (NYSE: XPEV) shares jumped 18.8% to $8.15 in pre-market tra

Insulet Corporation (NASDAQ:PODD ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President an

Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care Inc. shares plummeted more than 20% after the company reported earnings Wednesday, continuing a decline that has already cost the company two-thirds of its market value this year.

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.